Abstract
Background
This study aimed to explore the correlation between circular RNA_0000190 (circ_0000190) and microRNA-767-5p (miR-767-5p), and their correlations with biochemical indices, risk stratification, treatment response, and survival in multiple myeloma (MM) patients.
Methods
Bone marrow (BM) plasma cells of 86 MM patients (during standard diagnostic procedures) and 30 healthy donors (HDs) (examination of the eligibility for BM transplantation) were obtained, among which circ_0000190 and miR-767-5p expressions were detected using reverse transcription quantitative polymerase chain reaction. In MM patients, Durie‐Salmon stage and International Staging System (ISS) stage were assessed. Clinical responses (including complete response (CR) and objective response rate (ORR)) were assessed. The progression-free survival (PFS) and overall survival (OS) were calculated.
Results
Circ_0000190 was decreased, but miR-767-5p was increased in MM patients compared with HDs. Circ_0000190 was negatively correlated with miR-767-5p in both HDs and MM patients. In MM patients, circ_0000190 was negatively correlated with ISS stage, serum creatinine, beta-2-microglobulin, and lactate dehydrogenase but was positively correlated with albumin. Whereas an opposite trend in miR-767-5p was observed. Regarding clinical response, circ_0000190 had the value for predicting increased ORR, while miR-767-5p had the value for predicting decreased CR and ORR. Circ_0000190 high expression was correlated with better PFS and OS, while miR-767-5p high expression was correlated with worse PFS and OS. Multivariate Cox’s analyses revealed circ_0000190 high expression as an independent factor predicting better OS.
Conclusion
Circ_0000190 and its target miR-767-5p are dysregulated, and they are related to risk stratification and prognosis in MM patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F, Anderson KC (2017) Multiple myeloma Nature reviews Disease primers 3:17046
Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ(R)(2002): health professional version. In: PDQ Cancer Information Summaries. Bethesda (MD).
Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7(8):585–598
Wu L, Xia J, Yang J, Shi Y, Xia H, Xiang X, Yu X (2018) Circ-ZNF609 promotes migration of colorectal cancer by inhibiting Gli1 expression via microRNA-150. Journal of BUON : official journal of the Balkan Union of Oncology 23(5):1343–1349
Li S, Pei Y, Wang W, Liu F, Zheng K, Zhang X (2020) Extracellular nanovesicles-transmitted circular RNA has_circ_0000190 suppresses osteosarcoma progression. J Cell Mol Med 24(3):2202–2214
Chen S, Li T, Zhao Q, Xiao B, Guo J (2017) Using circular RNA hsa_circ_0000190 as a new biomarker in the diagnosis of gastric cancer. Clinica chimica acta; Int J Clin Chem 466:167–171.
Feng Y, Zhang L, Wu J, Khadka B, Fang Z, Gu J, Tang B, Xiao R, Pan G, Liu J (2019) CircRNA circ_0000190 inhibits the progression of multiple myeloma through modulating miR-767-5p/MAPK4 pathway. J Exp Clin Cancer Res: CR 38(1):54
Liu H, Wu Y, Wang S, Jiang J, Zhang C, Jiang Y, Wang X, Hong L, Huang H (2019) Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p. BMC Cancer 19(1):937
Gregorova J, Vrabel D, Radova L, Gablo NA, Almasi M, Stork M, Slaby O, Pour L, Minarik J, Sevcikova S [MicroRNA analysis for extramedullary multiple myeloma relapse]. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 31(Supplementum1):148–150.
(2016) [2014 International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma]. Nihon rinsho Japanese J Clin Med 74 Suppl 5:264–268.
Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R, National Comprehensive Cancer N (2015) Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw : JNCCN 13(11):1398–1435.
Guo J, McKenna SL, O’Dwyer ME, Cahill MR, O’Driscoll CM (2016) RNA interference for multiple myeloma therapy: targeting signal transduction pathways. Expert Opin Ther Targets 20(1):107–121
Zhang K, Guo L (2018) MiR-767 promoted cell proliferation in human melanoma by suppressing CYLD expression. Gene 641:272–278
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval
This study was approved by the Ethics Committee of our hospital, and the written informed consent according to the Declaration of Helsinki was acquired from each subject or his/her family member.
Competing interests
The authors declare that they have no competing interests.
Supplementary Information
Below is the link to the electronic supplementary material.
11845_2021_2586_MOESM1_ESM.tif
Supplementary file1 Supplementary Figure 1. Association of circ_0000190/miR-767-5p with R-ISS stage. Correlation of circ_0000190 with R-ISS stage (A); The correlation of miR-767-5p with R-ISS stage (B). Circ_0000190: circular RNA_0000190; miR-767-5p: microRNA-767-5p; R-ISS: revised International Staging System. (TIF 600 KB)
Rights and permissions
About this article
Cite this article
Xiang, Y., Xu, X., Yang, B. et al. Circular RNA_0000190 and its target microRNA-767-5p are dysregulated, and they are related to risk stratification as well as prognosis in multiple myeloma patients. Ir J Med Sci 191, 671–679 (2022). https://doi.org/10.1007/s11845-021-02586-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-021-02586-3